NEW YORK (GenomeWeb) – Institut Curie and Intel will collaborate to develop and implement bioinformatics tools, pipelines, and techniques to improve molecular profiling for research and clinical oncology, the partners said today.
As part of the collaboration, Institut Curie will have access to Intel experts to build and optimize a high-performance computing and artificial intelligence infrastructure to implement the Intel Genomics ecosystem, which includes partner solutions and best practices such as pipeline optimization from the Broad Institute for Cancer Genomics.
The partners also plan to develop tools to integrate and analyze heterogeneous biomedical data. The collaboration will specifically use Intel Select Solutions for Genomics Analytics based on the Intel Xeon scalable processors and Intel Omni-Path architecture.
Financial terms of the deal were not disclosed.
Emmanuel Barillot, head of the Institut Curie Bioinformatics platform and director of the Bioinformatics, Biostatistics, Epidemiology and Computational Systems Research Unit, noted in a statement that the partners will "develop, use, and implement innovative bioinformatics technologies to improve time to diagnosis, diagnostic accuracy, targeted treatment recommendations, and provide a better understanding of application needs to develop features that are needed for the healthcare sector."
Amaury Martin, lead of Institut Curie Technology Transfer and Industrial Partnerships Office and director of the Institut Carnot Curie Cancer, added that the partnership is an additional asset for the success of the SeqOIA (Sequencing, Omics, Information Analysis) project, a Paris-area platform cofounded last year by Assistance publique-Hôpitaux de Paris (AP-HP), Gustave-Roussy, and Institut Curie to implement genomic medicine in the region within the framework of the France Medicine Genomic 2025 Plan.